Optimized And Scalable LNP Composition For RNA Vaccine Delivery

By Natalie Orr (Presenting author), Mikayla Walsh, Cayden Yu, Victoria Hartman, Ian Johnston, Ashley Braun, Deepkanwal Singh Mundra, Ariel Zhang, Pierrot Harvie, Leanna Yee, Suraj Abraham, Nikita Jain, Anitha Thomas, Deo Tiwari, and Samuel Clarke

Lipid nanoparticle-encapsulated RNA (RNA-LNP) vaccines have been instrumental in the global response to the COVID-19 pandemic and are currently at various stages of clinical development for different infectious diseases. In this field, limited access to potent ionizable lipids and the expertise needed to optimize scalable formulations pose significant barriers to entry. To overcome these challenges, Precision NanoSystems developed a novel ionizable lipid along with a corresponding LNP composition. This formulation is optimized for vaccine delivery and scalable from bench to clinic.

Explore results from a study screening novel LNP formulations for physicochemical attributes, in vitro potency, and in vivo immunogenicity in both SARS-CoV-2 and influenza vaccine applications. Discover the storage stability and scalability of the lead LNP candidate as well as how this formulation can fast-track and de-risk drug development timelines.